Assertio Therapeutics Dividends
| ASRT Stock | USD 12.74 1.12 9.64% |
Dividends Paid is likely to gain to about 233 K in 2026. Dividend Paid And Capex Coverage Ratio is likely to gain to 95.38 in 2026. Assertio Therapeutics' past performance could be the main factor of why investors trade Assertio Therapeutics stock today. Investors should clearly understand every aspect of the Assertio Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Assertio Therapeutics' dividend schedule and payout information. Assertio Therapeutics dividends can also provide a clue to the current valuation of Assertio Therapeutics.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 221.9 K | 233 K | |
| Dividend Paid And Capex Coverage Ratio | 90.84 | 95.38 |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Assertio Therapeutics must own a stock before its ex-dividend date to receive its next dividend.
Assertio Therapeutics Dividends Paid Over Time
Today, most investors in Assertio Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Assertio Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Assertio Therapeutics dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Is there potential for Pharmaceuticals market expansion? Will Assertio introduce new products? Factors like these will boost the valuation of Assertio Therapeutics. If investors know Assertio will grow in the future, the company's valuation will be higher. Understanding fair value requires weighing current performance against future potential. All the valuation information about Assertio Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.19) | Earnings Share (4.50) | Revenue Per Share | Quarterly Revenue Growth 0.694 | Return On Assets |
Understanding Assertio Therapeutics requires distinguishing between market price and book value, where the latter reflects Assertio's accounting equity. The concept of intrinsic value - what Assertio Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Assertio Therapeutics' price substantially above or below its fundamental value.
Understanding that Assertio Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Assertio Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Assertio Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.